FENC · Fennec Pharmaceuticals Inc.
$10.65
-0.15 (-1.39%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$371.89M
Shares
35.07M
Volume · Sep 30
149.22K
Avg daily vol (3M)
198.99K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.80
Open$10.99
Day$10.64–11.11
52W close$5.77–12.78
Avg vol 30d220K
Short int545K · 1.6% float · 2.1d
Short vol30%
Last earningsAug 11, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 6 wks
filed Aug 13, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$59.22M
Trailing 12 months
Net income (TTM)
−$3.25M
Trailing 12 months
Revenue growth YoY
+85.2%
Year over year
Operating margin
-1.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+31.7%
Year over year · more shares
Price change (1Y)
+18.8%
Trailing year
Short interest
1.6%
Latest settlement · 2.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.38
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+22%
above
Price vs 50-day avg
−3%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
+66%
trailing
YTD return
+40%
this year
Relative strength
+53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $11 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$146.2K over 90 days · 100% sells
Short interest
Rising
1.55% of float · ▲ +4.7% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
106 holders — near 3-yr high, broad support
Squeeze score
54
elevated · 0–100
Fundamentals
Revenue growth
−6%
Y/Y
Gross margin
45%
expanding
EPS growth
−1600%
Y/Y
Free cash flow
$-12.5M
Balance sheet
$7.3M
net cash
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 11, 2026
Total cash OPEX
· 2026
$50M
Prior guidance
period ended
· from the Earnings Call filed Dec 31, 2025
Cash operating expenses
· 2025
$35M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+22%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $11 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+16% holders QoQ · +25 funds added
Insider flow
Distributing
Net -$146.2K over 90 days · 100% sells
Short interest
Rising
1.55% of float · ▲ +4.7% MoM · 2.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
106 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $11 · 72%
Range high $13
vs 200-day avg +22%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $2.8M | Three Months Ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net income $1.97M
-$287K Interest income
+$3K Interest expense
+$42K Provision for income taxes
+$0K Depreciation and amortization
-$710K Other revenue
+$1.77M Share based compensation expense
+$0K Unrealized loss on securities
+$6K Unrealized foreign exchange gain/(loss)
= Adjusted EBITDA $2.8M
|
|||
| Other revenue | $710K | Three Months Ended June 30, 2026 filing | — |
| PEDMARK product sales, net | $17.16M | Three Months Ended June 30, 2026 filing | +77.8% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FENC
this stock
Fennec Pharmaceuticals Inc.
|
$371.89M | +40.3% | -6.1% | — | 1.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +16.2% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -2.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FENC | -1.9% | -12.6% | +66.4% | -12.6% | +40.3% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -0.7% | -12.2% | +53.4% | -12.2% | +28.2% |